We help our customers make confident decisions with a clear understanding of their target biomarkers using Discovery’s high-quality biospecimen solutions, genomic biomarker services, and an array of pathologist-driven histopathology services including IHC services delivered on all leading technology platforms (Dako, Ventana, Leica, TechMate).
See the impact of Discovery’s Tissue Biomarker Services impact for yourself.
Establishing HER2 As A Companion Diagnostic Biomarker For The Treatment Of Breast & Gastric Cancers
Development of the Prototype Immunohistochemistry Assay that Advanced Development of Pembrolizumab
| Year | Authors | Title | Journal | PubMed ID | Snippet | Link |
|---|